Skip to content

Switch to tenofovir better than change to abacavir?

Switching to an NRTI-sparing HAART regimen can reduce fat loss

Low, detectable viral load on HAART associated with high levels of activated CD4 and CD8 T-cells

Low rate of treatment failure with tenofovir, 3TC and AZT

Tenofovir/ddI: is CD4 cell loss on treatment linked to this combination?

Kaletra effective and well tolerated in PI-experienced patients

ICAAC: Tenofovir and Trizivir effective and well-tolerated in patients who fail first regimen

Initial NNRTI-based HAART regimens are sustained longer than PI-based HAART, Canadian study shows

Keeping viral load below 20,000 copies/ml still beneficial, even after HIV rebound